AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.42), $0.14 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $57.7 million versus the consensus estimate of $58.1 million.

“Despite challenges posed in 2020 as a result of the pandemic, we made meaningful progress across our business with our strategic initiatives,” said Michael Carrel, President and Chief Executive Officer of AtriCure. “Looking ahead to 2021 and beyond, we are building on the strength of our core platform with key catalysts on the horizon which expand our market opportunities and position the company well for accelerated and sustainable revenue growth over the long term.”

GUIDANCE:

AtriCure sees Q1 2021 EPS of ($0.39)-($0.36), versus the consensus of ($0.21). AtriCure sees Q1 2021 revenue of $55-57 million, versus the consensus of $59.31 million.

AtriCure sees FY2021 EPS of ($1.15), versus the consensus of ($0.82). AtriCure sees FY2021 revenue of $250 million, versus the consensus of $257.1 million.

• Full year 2021 revenue is projected to be approximately $250 million. Continued uncertainty relating to the dynamic environment with the COVID-19 pandemic could materially impact this projection. Full year 2021 adjusted EBITDA is expected to be a loss of approximately $10 million and the full year 2021 adjusted loss per share approximately $1.15.
• First quarter 2021 revenue is expected to be in the range of $55 million to $57 million. First quarter 2021 adjusted EBITDA is expected to be a loss in the range of $5 million to $6 million. Adjusted loss per share for the first quarter 2021 is projected to be in the range of $0.36 to $0.39.

For earnings history and earnings-related data on AtriCure (ATRC) click here.